Black Titan (NASDAQ:BTTC) Posts Earnings Results

Black Titan (NASDAQ:BTTC) announced its quarterly earnings data on Friday. The company reported ($0.22) EPS for the quarter, FiscalAI reports.

Black Titan Stock Down 8.8%

Shares of BTTC stock traded down $0.09 during trading hours on Friday, reaching $0.90. The company had a trading volume of 56,156 shares, compared to its average volume of 740,814. Black Titan has a twelve month low of $0.86 and a twelve month high of $39.00. The stock has a market capitalization of $9.67 million, a P/E ratio of -0.30 and a beta of 1.20. The company’s fifty day simple moving average is $1.23.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Armistice Capital LLC bought a new position in Black Titan during the 4th quarter worth approximately $840,000. Marex Group plc bought a new position in Black Titan during the 4th quarter worth approximately $84,000. HRT Financial LP bought a new position in Black Titan during the 4th quarter worth approximately $28,000. Finally, Renaissance Technologies LLC bought a new position in Black Titan during the 4th quarter worth approximately $26,000.

About Black Titan

Titan Pharmaceuticals, Inc is a biopharmaceutical company developingproprietary therapeutics for the treatment of central nervous system disorders, cancer, and other serious and life threatening diseases. In the central nervous system arena, the company is developing iloperidone, which is clinical testing for schizophrenia through a licensing and development agreement with Novartis Pharma AG. Novartis has tradenamed the product Zomaril.